{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T19:19:45Z","timestamp":1787685585877,"version":"build-2784847793"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100011096","name":"Jazz Pharmaceuticals","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100011096","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1038\/s41375-026-03044-8","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T06:12:22Z","timestamp":1783923142000},"page":"1977-1984","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Randomized phase 2 trial of CPX-351 vs. CLAG-M (cladribine, cytarabine, G-CSF, and mitoxantrone) for medically unfit adults with acute myeloid leukemia or other high-grade myeloid neoplasms"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4326-0748","authenticated-orcid":false,"given":"Anna B.","family":"Halpern","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8176-6371","authenticated-orcid":false,"given":"Megan","family":"Othus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary-Elizabeth M.","family":"Percival","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Ghiuzeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob S.","family":"Appelbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul C.","family":"Hendrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan D.","family":"Cassaday","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart L.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0023-8054","authenticated-orcid":false,"given":"Jason P.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua R.","family":"Veatch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siob\u00e1n B.","family":"Keel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian G.","family":"Oehler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1885-1773","authenticated-orcid":false,"given":"Erik L.","family":"Kimble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raya","family":"Mawad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9268-3341","authenticated-orcid":false,"given":"Roland B.","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"key":"3044_CR1","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1200\/JCO.1989.7.9.1268","volume":"7","author":"B L\u00f6wenberg","year":"1989","unstructured":"L\u00f6wenberg B, Zittoun R, Kerkhofs H, Jehn U, Abels J, Debusscher L, et al. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol. 1989;7:1268\u201374.","journal-title":"J Clin Oncol"},{"key":"3044_CR2","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1200\/JCO.1984.2.8.865","volume":"2","author":"SB Kahn","year":"1984","unstructured":"Kahn SB, Begg CB, Mazza JJ, Bennett JM, Bonner H, Glick JH. Full dose versus attenuated dose daunorubicin, cytosine arabinoside, and 6-thioguanine in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol. 1984;2:865\u201370.","journal-title":"J Clin Oncol"},{"key":"3044_CR3","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1200\/JCO.1990.8.2.272","volume":"8","author":"H Tilly","year":"1990","unstructured":"Tilly H, Castaigne S, Bordessoule D, Casassus P, Le Pris\u00e9 PY, Tertian G, et al. Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol. 1990;8:272\u20139.","journal-title":"J Clin Oncol"},{"key":"3044_CR4","doi-asserted-by":"crossref","unstructured":"DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133-7-17.","DOI":"10.1182\/blood-2018-08-868752"},{"key":"3044_CR5","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/leu.2014.216","volume":"29","author":"RB Walter","year":"2015","unstructured":"Walter RB, Estey EH. Management of older or unfit patients with acute myeloid leukemia. Leukemia. 2015;29:770\u20135.","journal-title":"Leukemia"},{"key":"3044_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100679","volume":"44","author":"RB Walter","year":"2020","unstructured":"Walter RB, Estey EH. Selection of initial therapy for newly-diagnosed adult acute myeloid leukemia: Limitations of predictive models. Blood Rev. 2020;44:100679.","journal-title":"Blood Rev"},{"key":"3044_CR7","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s00432-025-06314-7","volume":"151","author":"A Tuerxun","year":"2025","unstructured":"Tuerxun A, Yang Y, Cai X, Chen X, Zhao Z, Zhao Y, et al. Prediction models for different types of leukemia: a systematic review and critical appraisal. J Cancer Res Clin Oncol. 2025;151:268.","journal-title":"J Cancer Res Clin Oncol"},{"key":"3044_CR8","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1038\/leu.2012.303","volume":"27","author":"F Ferrara","year":"2013","unstructured":"Ferrara F, Barosi G, Venditti A, Angelucci E, Gobbi M, Pane F, et al. Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making. Leukemia. 2013;27:997\u20139.","journal-title":"Leukemia"},{"key":"3044_CR9","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912\u20139.","journal-title":"Blood"},{"key":"3044_CR10","doi-asserted-by":"crossref","unstructured":"Sorror ML, Storer BE, Fathi AT, Gerds AT, Medeiros BC, Shami P, et al. Development and validation of a novel acute myeloid leukemia-composite model to estimate risks of mortality. JAMA Oncol. 2017;3:1675\u201382.","DOI":"10.1001\/jamaoncol.2017.2714"},{"key":"3044_CR11","doi-asserted-by":"publisher","first-page":"4417","DOI":"10.1200\/JCO.2011.35.7525","volume":"29","author":"RB Walter","year":"2011","unstructured":"Walter RB, Othus M, Borthakur G, Ravandi F, Cortes JE, Pierce SA, et al. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol. 2011;29:4417\u201323.","journal-title":"J Clin Oncol"},{"key":"3044_CR12","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/ajh.26061","volume":"96","author":"A Maiti","year":"2021","unstructured":"Maiti A, Qiao W, Sasaki K, Ravandi F, Kadia TM, Jabbour EJ, et al. Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality. Am J Hematol. 2021;96:282\u201391.","journal-title":"Am J Hematol"},{"key":"3044_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.97","volume":"5","author":"SA Buckley","year":"2015","unstructured":"Buckley SA, Othus M, Estey EH, Walter RB. The treatment-related mortality score is associated with non-fatal adverse events following intensive AML induction chemotherapy. Blood Cancer J. 2015;5:e276.","journal-title":"Blood Cancer J"},{"key":"3044_CR14","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.3109\/10428194.2015.1135436","volume":"57","author":"CD Godwin","year":"2016","unstructured":"Godwin CD, Othus M, Powell MA, Buckley SA, Estey EH, Walter RB. Prediction of early death in adults with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma. 2016;57:2421\u20134.","journal-title":"Leuk Lymphoma"},{"key":"3044_CR15","doi-asserted-by":"crossref","unstructured":"Zarling LC, Othus M, Sandmaier BM, Milano F, Schoch G, Davis C, et al. Utility of the treatment-related mortality (TRM) score to predict outcomes of adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation. Leukemia. 2022;36:1563\u201374.","DOI":"10.1038\/s41375-022-01574-5"},{"key":"3044_CR16","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1080\/10428194.2025.2571201","volume":"67","author":"H Ichimura","year":"2026","unstructured":"Ichimura H, Kato S, Monna-Oiwa M, Andoh S, Kuroda J, Kondo K, et al. Comparative analysis of the acute myeloid leukemia-composite model and treatment-related mortality score in single-unit cord blood transplantation. Leuk Lymphoma. 2026;67:229\u201332.","journal-title":"Leuk Lymphoma"},{"key":"3044_CR17","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.3324\/haematol.2017.182642","volume":"103","author":"RB Walter","year":"2018","unstructured":"Walter RB, Othus M, Orlowski KF, McDaniel EN, Scott BL, Becker PS, et al. Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm. Haematologica. 2018;103:e106\u2013e109.","journal-title":"Haematologica"},{"key":"3044_CR18","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1038\/s41375-022-01524-1","volume":"36","author":"AB Halpern","year":"2022","unstructured":"Halpern AB, Othus M, Alcorn G, Ali Z, Garcia KA, Percival MM, et al. Physician and patient perceptions on randomization of treatment intensity for unfit adults with acute myeloid leukemia and other high-grade myeloid neoplasm. Leukemia. 2022;36:1386\u20139.","journal-title":"Leukemia"},{"key":"3044_CR19","doi-asserted-by":"crossref","unstructured":"Palmieri R, Othus M, Halpern AB, Percival MM, Godwin CD, Becker PS, et al. Accuracy of SIE\/SIES\/GITMO consensus criteria for unfitness to predict early mortality after intensive chemotherapy in adults with AML or other high-grade myeloid neoplasm. J Clin Oncol. 2020;38:4163\u201374.","DOI":"10.1200\/JCO.20.01392"},{"key":"3044_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2026.102605","volume":"87","author":"A Sperotto","year":"2026","unstructured":"Sperotto A, Ciotti G, Basso M, Gottardi M. CPX-351: From preclinical studies to future directions. Curr Opin Pharmacol. 2026;87:102605.","journal-title":"Curr Opin Pharmacol"},{"key":"3044_CR21","doi-asserted-by":"crossref","unstructured":"Shimony S, Murdock HM, Keating J, Tsai HK, Sasi A, Gibson CJ, et al. CPX-351 selectively benefits patients with AML and myelodysplasia-related mutations in the pivotal randomized trial. Blood Adv. 2026;10:2854\u201364.","DOI":"10.1182\/bloodadvances.2025019378"},{"key":"3044_CR22","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424\u201347.","journal-title":"Blood"},{"key":"3044_CR23","doi-asserted-by":"crossref","unstructured":"Wood BL. Acute myeloid leukemia minimal residual disease detection: the difference from normal approach. Curr Protoc Cytom. 2020;93:e73.","DOI":"10.1002\/cpcy.73"},{"key":"3044_CR24","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3324\/haematol.2022.281631","volume":"108","author":"E Rodr\u00edguez-Arbol\u00ed","year":"2023","unstructured":"Rodr\u00edguez-Arbol\u00ed E, Othus M, Orvain C, Zarling LC, Sandmaier BM, Milano F, et al. Contribution of measurable residual disease status to prediction accuracy of relapse and survival in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation. Haematologica. 2023;108:273\u20137.","journal-title":"Haematologica"},{"key":"3044_CR25","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1182\/blood.2021014804","volume":"139","author":"G Paras","year":"2022","unstructured":"Paras G, Morsink LM, Othus M, Milano F, Sandmaier BM, Zarling LC, et al. Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML. Blood. 2022;139:1694\u2013706.","journal-title":"Blood"},{"key":"3044_CR26","doi-asserted-by":"crossref","unstructured":"Araki D, Wood BL, Othus M, Radich JP, Halpern AB, Zhou Y, et al. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease-based definition of complete remission? J Clin Oncol. 2016;34:329\u201336.","DOI":"10.1200\/JCO.2015.63.3826"},{"key":"3044_CR27","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1200\/JCO.2010.31.8121","volume":"29","author":"RB Walter","year":"2011","unstructured":"Walter RB, Gooley TA, Wood BL, Milano F, Fang M, Sorror ML, et al. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. J Clin Oncol. 2011;29:1190\u20137.","journal-title":"J Clin Oncol"},{"key":"3044_CR28","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365\u201376.","journal-title":"J Natl Cancer Inst"},{"key":"3044_CR29","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41375-019-0586-6","volume":"34","author":"AB Halpern","year":"2020","unstructured":"Halpern AB, Howard NP, Othus M, Hendrie PC, Baclig NV, Buckley SA, et al. Early hospital discharge after intensive induction chemotherapy for adults with acute myeloid leukemia or other high-grade myeloid neoplasm. Leukemia. 2020;34:635\u20139.","journal-title":"Leukemia"},{"key":"3044_CR30","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1080\/10428194.2021.1984451","volume":"63","author":"AB Halpern","year":"2022","unstructured":"Halpern AB, Othus M, Howard NP, Hendrie PC, Percival MM, Hartley GA, et al. Comparative analysis of infectious complications with outpatient vs. inpatient care for adults with high-risk myeloid neoplasm receiving intensive induction chemotherapy. Leuk Lymphoma. 2022;63:142\u201351.","journal-title":"Leuk Lymphoma"},{"key":"3044_CR31","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1080\/10428194.2020.1821008","volume":"62","author":"AB Halpern","year":"2021","unstructured":"Halpern AB, Othus M, Howard NP, Hendrie PC, Percival MM, Scott BL, et al. Comparison of outpatient care following intensive induction versus post-remission chemotherapy for adults with acute myeloid leukemia and other high-grade myeloid neoplasms. Leuk Lymphoma. 2021;62:234\u20138.","journal-title":"Leuk Lymphoma"},{"key":"3044_CR32","doi-asserted-by":"crossref","unstructured":"Krauss AC, Gao X, Li L, Manning ML, Patel P, Fu W, et al. FDA approval summary: (daunorubicin and cytarabine) liposome for injection for the treatment of adults with high-risk acute myeloid leukemia. Clin Cancer Res. 2019;25:2685\u201390.","DOI":"10.1158\/1078-0432.CCR-18-2990"},{"key":"3044_CR33","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1182\/blood.2021014586","volume":"140","author":"ES Wang","year":"2022","unstructured":"Wang ES, Montesinos P, Minden MD, Lee JH, Heuser M, Naoe T, et al. Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy. Blood. 2022;140:1845\u201357.","journal-title":"Blood"},{"key":"3044_CR34","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1182\/blood.2021014901","volume":"141","author":"S de Botton","year":"2023","unstructured":"de Botton S, Montesinos P, Schuh AC, Papayannidis C, Vyas P, Wei AH, et al. Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed\/refractory AML: a randomized phase 3 trial. Blood. 2023;141:156\u201367.","journal-title":"Blood"},{"key":"3044_CR35","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1182\/blood-2013-04-496596","volume":"122","author":"AK Burnett","year":"2013","unstructured":"Burnett AK, Russell NH, Hunter AE, Milligan D, Knapper S, Wheatley K, et al. Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival. Blood. 2013;122:1384\u201394.","journal-title":"Blood"},{"key":"3044_CR36","doi-asserted-by":"publisher","first-page":"4539","DOI":"10.1182\/bloodadvances.2023010276","volume":"7","author":"J Othman","year":"2023","unstructured":"Othman J, Wilhelm-Benartzi C, Dillon R, Knapper S, Freeman SD, Batten LM, et al. A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial. Blood Adv. 2023;7:4539\u201349.","journal-title":"Blood Adv"},{"key":"3044_CR37","doi-asserted-by":"crossref","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617\u201329.","DOI":"10.1056\/NEJMoa2012971"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03044-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03044-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03044-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T19:01:40Z","timestamp":1787684500000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03044-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["3044"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-03044-8","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]},"assertion":[{"value":"16 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.B.H\n                      . received clinical trial support from Merck, Jazz, Incyte, Karyopharm, Disc Medicine, Protagonist, PharmEssentia, Sumitomo, and Chordia and consulting fees from BMS and Karyopharm.\n                      R.B.W\n                      . has received laboratory research grants and\/or clinical trial support from ImmunoGen\/AbbVie, Jazz, and Kura, and has been a consultant to AbbVie, Arog, Cullinan, and Syndax.\n                      R.D.C\n                      . has received clinical trial support from Amgen, Incyte, Kite\/Gilead, Pfizer, and Servier; consulting\/honoraria from Astra Zeneca, Autolus, Cycle Pharma, Kite\/Gilead, Merck, Pfizer, Sana Biotechnologies, Servier, and Takeda; and served on a board or advisory committee for Autolus and PeproMene Bio\n                      . E.L.K\n                      . receives research funding from Juno Therapeutics (a Bristol Myers Squibb Company), ScaleReady LLC, Cell Signaling Technology; is an Inventor on patents related to CAR T-cell therapy; and is the beneficiary of licensing agreements with Cell Signaling Technology.\n                      M.M.P\n                      . has received research funding from Abbvie, Ascentage, Astex, Oncoverity, and Pfizer. All authors revised the manuscript critically and gave final approval to submit for publication.\n                      M.O\n                      . has received consulting fees from Merck, Refined Oncology, and Biosight and serves on independent data safety monitoring boards for Bristol Myers Squibb, Glycomimetics, and Grifols.\n                      V.G.O\n                      . receives research funding from Pfizer and has received consulting fees from Novartis, Terns and Takeda,\n                      J.R.V\n                      . owns stock in NovoNordisk and receives advising fees from Hox Bio.\n                      B.L.S\n                      . receives research funding from Novartis, consulting fees from Incyte, BMS, Alexion, Aztraseneca and sits on an advisory panel for Orca Bio T.\n                      C.G\n                      . owns stock in Pfizer, Intellia, Crispr genomics, Sanofi, Syndax, Vertex, TG therapeutics, Axsome, Bristol-Meyers, Ionis, and Repare therapeutics.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All patients were treated at the Fred Hutchinson Cancer Center (Fred Hutch) and the University of Washington Medical Center. The protocol (ClinicalTrials.gov:\n                      NCT04195945\n                      ) was approved by the Fred Hutch Institutional Review Board (IRB) and informed consent was obtained from all participants in accordance with the Declaration of Helsinki. All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}